AU782569B2 - Therapeutic binding agents against MUC-1 antigen and methods of their use - Google Patents

Therapeutic binding agents against MUC-1 antigen and methods of their use Download PDF

Info

Publication number
AU782569B2
AU782569B2 AU69211/00A AU6921100A AU782569B2 AU 782569 B2 AU782569 B2 AU 782569B2 AU 69211/00 A AU69211/00 A AU 69211/00A AU 6921100 A AU6921100 A AU 6921100A AU 782569 B2 AU782569 B2 AU 782569B2
Authority
AU
Australia
Prior art keywords
binding agent
tumor
mammal
muc
therapeutically treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU69211/00A
Other languages
English (en)
Other versions
AU6921100A (en
Inventor
Ragupathy Madiyalakan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoquest Inc
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Publication of AU6921100A publication Critical patent/AU6921100A/en
Assigned to ALTAREX MEDICAL CORP. reassignment ALTAREX MEDICAL CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: ALTAREX CORP.
Application granted granted Critical
Publication of AU782569B2 publication Critical patent/AU782569B2/en
Assigned to ONCOQUEST INC. reassignment ONCOQUEST INC. Alteration of Name(s) in Register under S187 Assignors: ALTAREX MEDICAL CORP.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU69211/00A 1999-08-18 2000-08-18 Therapeutic binding agents against MUC-1 antigen and methods of their use Ceased AU782569B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14949299P 1999-08-18 1999-08-18
US60/149492 1999-08-18
US16471499P 1999-11-11 1999-11-11
US60/164714 1999-11-11
PCT/US2000/022890 WO2001012217A1 (en) 1999-08-18 2000-08-18 Therapeutic antibody against muc-1 antigen and methods for their use

Publications (2)

Publication Number Publication Date
AU6921100A AU6921100A (en) 2001-03-13
AU782569B2 true AU782569B2 (en) 2005-08-11

Family

ID=26846783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69211/00A Ceased AU782569B2 (en) 1999-08-18 2000-08-18 Therapeutic binding agents against MUC-1 antigen and methods of their use

Country Status (7)

Country Link
EP (1) EP1204423B1 (enExample)
JP (2) JP2003519096A (enExample)
AT (1) ATE290879T1 (enExample)
AU (1) AU782569B2 (enExample)
DE (1) DE60018761T2 (enExample)
ES (1) ES2239032T3 (enExample)
WO (1) WO2001012217A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2002058450A2 (en) 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
US6627664B2 (en) * 2001-01-30 2003-09-30 Altachem Pharma Ltd. Perylenequinones for use as sonosensitizers
US20040110846A1 (en) * 2001-01-30 2004-06-10 Beatrice Leveugle Perylenequinones for use with immunotherapy agents
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
AU2002358246B2 (en) * 2001-10-26 2008-02-28 Oncoquest Pharmaceuticals Inc. Combination therapy for treating disease
CN100356984C (zh) * 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
US8506931B2 (en) 2005-08-10 2013-08-13 Quest Pharmatech Inc. Perylenequinone derivatives and uses thereof
US8454991B2 (en) 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
CA2741798A1 (en) 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2011135869A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なｍｕｃ１抗体
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
EP2748302B1 (en) 2011-08-22 2018-08-15 Glycotope GmbH Microorganisms carrying a tumor antigen
JP2017009287A (ja) * 2013-11-11 2017-01-12 東ソー株式会社 前立腺癌と前立腺肥大症との識別方法
JP6476170B2 (ja) 2014-04-28 2019-03-06 医化学創薬株式会社 抗ｍｕｃ１抗体又はその抗原結合性断片及びその用途
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020841A1 (en) * 1992-04-13 1993-10-28 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
FI950062A7 (fi) * 1992-07-06 1995-01-05 Biomira Inc Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
DE19534630A1 (de) * 1995-09-18 1997-03-20 Max Delbrueck Centrum Monoklonale Antikörper gegen epitheliales Muzin (MUC1)
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
AU6017198A (en) * 1997-01-10 1998-08-25 Altarex Corp. Substituted perylenequinones for use in photodynamic therapy
EP1056472A2 (en) * 1998-02-13 2000-12-06 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Specific antibodies against mammary tumor-associated mucin, method for production and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROC. AM. ASSOC. CANCER RESEARCH VOL 39 P 367 #2500 *

Also Published As

Publication number Publication date
AU6921100A (en) 2001-03-13
ATE290879T1 (de) 2005-04-15
JP2003519096A (ja) 2003-06-17
WO2001012217A1 (en) 2001-02-22
DE60018761T2 (de) 2006-02-02
EP1204423A1 (en) 2002-05-15
JP2012046518A (ja) 2012-03-08
EP1204423B1 (en) 2005-03-16
WO2001012217A9 (en) 2002-06-27
ES2239032T3 (es) 2005-09-16
DE60018761D1 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
US6716966B1 (en) Therapeutic binding agents against MUC-1 antigen and methods for their use
US7147850B2 (en) Therapeutic binding agents against MUC-1 antigen and methods for their use
EP1204423B1 (en) Therapeutic antibody against muc-1 antigen and methods for their use
US8444974B2 (en) Use of antibodies for the vaccination against cancer
TWI672318B (zh) 葉酸受體１抗體類和免疫共軛物類及彼等之用途
JP2002515235A (ja) 坑アミロイド抗体を用いるアミロイドの除去方法
US20080014210A1 (en) Peptides and antibodies to muc 1 proteins
TW201726175A (zh) 新穎抗密連蛋白（ｃｌａｕｄｉｎ）抗體及使用方法
JP2002518347A (ja) 前立腺癌治療のための免疫療法組成物および方法
EP0556285A1 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
WO1999040881A2 (en) Specific antibodies against mammary tumor-associated mucin, method for production and use
CZ20021707A3 (cs) Pouľití protilátek pro výrobu farmaceutického přípravku vhodného jako vakcína
JP2002518342A (ja) 抗原を変化させることにより免疫応答を産生する治療組成物
JP2526217B2 (ja) 腫瘍会合性糖蛋白に対するモノクロ−ナル抗体およびそれらの製法
Oldham et al. Individually specified drug immunoconjugates in cancer treatment
CA2380936A1 (en) Therapeutic antibody against muc-1 antigen and methods for their use
US20040265318A1 (en) Use of antibodies for the vaccination against cancer
AU650080B2 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTION TITLE TO READ: THERAPEUTIC BINDING AGENTS AGAINST MUC-1 ANTIGEN AND METHODS OF THEIR USE

PC1 Assignment before grant (sect. 113)

Owner name: ALTAREX MEDICAL CORP.

Free format text: THE FORMER OWNER WAS: ALTAREX CORP